SEC Comment Letter for RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426) — Feb 11, 2020
RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426)
Date: Feb. 11, 2020 · CIK: 0001739426 · Accession: 0000000000-20-001248
AI Filing Summary & Sentiment
File numbers found in text: 333-236193
Letter
February 7, 2020 Brian Markison Chief Executive Officer Osmotica Pharmaceuticals plc 400 Crossing Boulevard Bridgewater, NJ 08807 Re:Osmotica Pharmaceuticals plc Registration Statement on Form S-3 Filed January 31, 2020 File No. 333-236193 Dear Mr. Markison: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig Marcus, Esq.
Show Raw Text
February 7, 2020
Brian Markison
Chief Executive Officer
Osmotica Pharmaceuticals plc
400 Crossing Boulevard
Bridgewater, NJ 08807
Re:Osmotica Pharmaceuticals plc
Registration Statement on Form S-3
Filed January 31, 2020
File No. 333-236193
Dear Mr. Markison:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Craig Marcus, Esq.